Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1570-1577

  Ohara, Shinya ^a   Oue, Naohide ^a   Matsubara, Akio ^a   Mita, Koji ^a   Hasegawa, Yasuhisa ^a   Hayashi, Tetsutaro ^a   Usui, Tsuguru ^a   Amatya, Vishwa Jeet ^a   Takeshima, Yukio ^a   Kuniyasu, Hiroki ^b   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CHROMOGRANIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN 2; PROSTATE SPECIFIC ANTIGEN; PROTEIN REG 4; TUMOR MARKER;

ANIMAL CELL; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN PHOSPHORYLATION; RELAPSE FREE SURVIVAL; WESTERN BLOTTING;

BLOTTING, WESTERN; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS, C-TYPE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 49749083010     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00846.x     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. D'Amico AV, Whittington R, Malkowicz SB et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18: 1164-72.
3. Oue N, Hamai Y, Mitani Y et al. Gene expression profile of gastric carcinoma: Identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 2004; 64: 2397-405.
4. Aung PP, Oue N, Mitani Y et al. Systematic search for gastric cancer-specific genes based on SAGE data: Melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006; 25: 2546-57.
5. Oue N, Mitani Y, Aung PP et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J Pathol 2005; 207: 185-98.
6. Mitani Y, Oue N, Matsumura S et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 2007; 26: 4383-93.
7. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002; 2: 113-16.
8. Hasegawa Y, Matsubara A, Teishima J et al. DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer. Cancer Sci 2007; 98: 32-6.
9. Oue N, Kuniyasu H, Noguchi T et al. Serum concentration of Reg IV in patients with colorectal cancer: Overexpression and high serum levels of Reg IV are associated with liver metastasis. Oncology, 2007; 72: 371-80.
10. Takehara A, Eguchi H, Ohigashi H et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006; 97: 1191-7.
11. Gu Z, Rubin MA, Yang Y et al. Reg IV: A promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res 2005; 11: 2237-43.
12. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 2006; 130: 137-49.
13. Yasui W, Ayhan A, Kitadai Y et al. Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 1993; 53: 36-41.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
15. Nanakin A, Fukui H, Fujii S et al. Expression of the REG IV gene in ulcerative colitis. Lab Invest 2007; 87: 304-14.
16. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 1994; 152: 2120-4.
17. Culig Z, Hobisch A, Cronauer MV et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
18. Connolly JM, Rose DP. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 1998; 160: 932-6.
19. Bonaccorsi L, Carloni V, Muratori M et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78-86.
20. Huggins C. Endocrine-induced regression of cancers. Science 1967; 156: 1050-4.
21. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
22. Shah RB, Ghosh D, Elder JT. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence. Prostate 2006; 66: 1437-44.
23. Legrier ME, de Pinieux G, Boye K et al. Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft. Br J Cancer 2004; 90: 720-7.
24. McWilliam LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997; 80: 287-90.
25. di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78: 357-61.